Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.

Bioorganic & medicinal chemistry letters - 1 Sept 2020

Nakamura Hiroshi, Fujioka Shingo, Terui Takashi, Okuda Satoshi, Kondo Kentaro, Tamatani Yoshinori, Akagi Yusuke, Komoda Yasumasa, Kinoshita Wataru, Ito Soichiro, Maeda Kimiya, Ukaji Yutaka, Inaba Takashi

Abstract excerpt

A novel unsymmetrical structural class of orally bioavailable hepatitis C virus (HCV) nonstructural 5A protein (NS5A) inhibitors has been generated by improving both the solubility and membrane permeability of the lead compound found in our previous work. The representative compound 14, with a 5-hydroxymethylpyrazine group and a 3-t-butylpropargyl group on each side of the molecule, exhibited the best oral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pyrazines
Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to Hepacivirus

Share to Hepatitis C

Share to Structure-Activity Relationship

Share to Viral Nonstructural Proteins

Share to Virus Replication

Source

Identifiers

PMID: 32738974
DOI: 10.1016/j.bmcl.2020.127361

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.PMID 32738974Read ↗

Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.Semantic proximity Read ↗

Synthesis, biological evaluation and in silico modeling of novel pan-genotypic NS5A inhibitors.Semantic proximity Read ↗

Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.Semantic proximity Read ↗

Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase.Semantic proximity Read ↗

Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase.Semantic proximity Read ↗

Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs.Semantic proximity Read ↗

Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.Semantic proximity Read ↗

Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor.Semantic proximity Read ↗

Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.Semantic proximity Read ↗

Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity.Semantic proximity Read ↗

Structure-activity relationships of fluorene compounds inhibiting HCV variants.Semantic proximity Read ↗

GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.